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Background: An early detection of precursor lesions of cervical cancer will help to eliminate 
the worldwide burden of cervical cancer.
Methods: This exploratory study aimed to identify, by matrix-assisted laser desorption/ 
ionization (MALDI) time-of-flight (TOF) mass spectrometry (MS), serum protein profiles that 
distinguish cervical intraepithelial neoplasia grades CIN 1 or lower (#CIN 1) from CIN 2+ 
among 127 women infected with human papillomavirus (HPV) 16. Of these 127 women, 
25 and 23 were diagnosed with CIN 2 or CIN 3, respectively (cases), and 79 were diagnosed 
with #CIN 1 (non-cases). Serum protein profiles were generated by MALDI-TOF-MS. A total 
of 95 m/z peaks were tested for association with case status by two racial groups, African 
American (AAs) and Caucasian American (CAs).
Results: Overall, 2 protein peaks identified by our study demonstrated higher specificity for 
identifying CIN 2+ than previously published studies. An increasing intensity of [m/z 4459] 
was associated with a higher risk of being a case, regardless of race with a specificity of 58% 
for CIN 2 and a specificity of 75% for CIN 3. An increasing intensity of [m/z 4154] was not 
only associated with a higher risk of being a case only among CAs, but also had an opposite 
effect among AAs.
Conclusion: Identification of specific proteins associated with the peaks detected in serum 
and development of antibody-based tests such as ELISA should lead to the development of race-
specific, non-invasive and cost effective screening tests with higher specificity for identifying 
HPV 16 associated CIN 2+.
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Introduction
Worldwide, cervical cancer (CC), which is caused mainly by 13 high-risk or 
  carcinogenic genotypes of human papillomaviruses (HPVs), is the third most 
prevalent type of cancer in women.1,2 HPV is the most common sexually transmitted 
virus.3 In addition, HPV infections and CC risks are compounded by infections with 
human   immunodeficiency virus (HIV) and the resulting acquired immune deficiency 
syndrome.4,5 Although CC is a priority global health condition affecting millions of 
women, it is preventable by use of organized screening programs and regular follow-up 
of at-risk women. A cytology-based screening test for CC (Pap test) has been used 
in high-income countries for the last 50 years. Compared with cytology, testing for 
HPVs is more sensitive in detecting cervical intraepithelial neoplasia grades CIN 2+, 
but with lower specificity.6 For much of the world, screening by the Pap test or by 
HPV tests may not however, be a viable option because of the need for specialized International Journal of Women’s Health 2011:3 submit your manuscript | www.dovepress.com
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practitioners or lack of laboratory infrastructure to perform 
these tests. Therefore, development of improved screening 
tools that can be applied worldwide, and without the need 
for such infrastructure, will greatly aid in the prevention and 
control of CC.
We have previously conducted an exploratory study 
to identify candidate surface-enhanced laser desorption/
ionization (SELDI) time of flight (TOF) mass spectrometry 
(MS) protein profiles in plasma that may distinguish cervical 
intraepithelial neoplasia 3 (CIN 3) from CIN 1 among women 
infected with high-risk HPVs. The results of this study sug-
gested the possibility of using plasma SELDI protein profiles 
to identify women who are likely to have CIN 3 lesions.7 The 
current report describes an exploratory study to identify, by 
matrix-assisted laser desorption/  ionization (MALDI) TOF 
MS, protein profiles in serum that may distinguish CIN 1 or 
lower (#CIN 1) from CIN 2+ among AA and CA women 
infected with HPV 16, one of the most carcinogenic types 
of HPVs.
Materials and methods
Patient population
The study is based on the analysis of serum samples from 
127 HPV 16 positive women who were enrolled in a pro-
spective follow-up study funded by the National Cancer 
Institute (R01 CA105448, Prognostic Significance of DNA 
and Histone Methylation). The study has been described in 
a previous publication.8 All women were diagnosed with 
abnormal cervical cells in clinics of the Health Departments 
in Jefferson County and surrounding counties in Alabama and 
were referred to the University of Alabama at Birmingham 
(UAB) for further examination by colposcopy and biopsy. 
The women were 19–50 years old, had no history of cervical 
cancer or other cancers of the lower genital tract, no history 
of hysterectomy or destructive therapy of the cervix, were 
not pregnant, and were not using antifolate medications 
such as methotrexate, sulfasalazine, or phenytoin. Of these 
127 women, 25 and 23 were diagnosed with CIN 2 or CIN 3, 
respectively (cases), and 79 were diagnosed with #CIN 1 
(normal cervical epithelium, n = 3, HPV cytopathic effect, 
n = 6, reactive nuclear enlargement, n = 15 or CIN 1, n = 55, 
non-cases). All women tested positive for HPV 16 in exfo-
liated cervical cells. All women included in this analysis 
participated in an interview that assessed sociodemographic 
variables and lifestyle risk factors. Height and weight mea-
surements were obtained by use of standard protocols. The 
BMI was calculated using the height and weight measure-
ments (weight kg/[height m]2). Pelvic examinations and 
collection of cervical cells and biopsies were accomplished 
following the protocols of the colposcopy clinic. Fasting 
blood samples were collected from all women and processed 
immediately to isolate serum. Several serum sample aliquots 
were stored at −80°C. Serum samples which were not sub-
jected to freeze-thaw cycles were used to generate serum 
protein profiles. The study protocol and procedures were 
approved by the UAB Institutional Review Board.
Testing for HPVs
DNA was extracted from cervical cells using the QIAamp 
MiniElute Media Kit (Qiagen, Inc, Valencia, CA) following 
the manufacturer’s instruction for HPV genotyping test. 
HPV genotyping test (Linear Array, Roche Diagnostics, 
Indianapolis, IN) was performed according to the manu-
facturer’s instructions by a research associate trained by 
personnel from Roche Diagnostics. Briefly, target DNA 
amplified by Polymerase Chain Reaction (PCR) utilized 
the PGMY09/11 L1 consensus primer system and included 
co-amplification of a human cellular target, β-globin, as 
an internal control. Detection and HPV genotyping were 
achieved using a linear array HPV genotyping test and this 
test included probes to genotype for 37 anogenital HPV types 
(6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 42, 45, 51, 52, 53, 54, 55, 
56, 58, 59, 61, 62, 64, 66, 67, 68, 69, 70, 71, 72, 73 (MM9), 
81, 82 (MM4), 83 (MM7), 84 (MM8), IS39, and CP6108). 
HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68 were 
considered to be high-risk (HR) HPV types and all other 
types were considered to be low-risk (LR) HPVs.
Generation of serum protein profiles
A high-affinity, solid-core lipophilic extraction resin was 
used to enrich the low-molecular-weight protein fraction of 
the samples. Bondapak C18 125A, 37–55 µm resin (Waters, 
Milford, MA, USA) was packed into 96-well, 0.45-µm 
Unifilter plates (Whatman, Florham Park, NJ, USA) and the 
packed resins were activated with 80% acetonitrile (aque-
ous). Serum samples were thawed, diluted (1:50) in distilled 
water, acidified by adding trifluoroacetic acid (TFA) to a 
final concentration of 1% v/v (475 µL of sample plus 25 µL 
of 20% TFA), and mixed with the activated C18 resins. The 
unbound serum proteins were removed by centrifugation 
of the 96-well plate for 5 minutes at 1500 g. The resin was 
washed twice with 200 µL of 1% TFA per well, and the 
bound peptides and low-molecular-weight proteins were 
eluted with 100 µl of 70% CH3CN:0.1% TFA (aqueous). 
Eluants were mixed with an equal volume of matrix consist-
ing of 20 mg/mL sinapinic acid (Fluka, St Louis, MO, USA) International Journal of Women’s Health 2011:3 submit your manuscript | www.dovepress.com
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in 50:50 CH3CN:0.1% TFA) and spotted onto a MALDI 
target plate for MALDI-TOF analysis. Profiles of peptides 
and low-molecular-weight proteins were obtained using a 
200 Hz MALDI-TOF/TOF MS (Ultraflex III, Bruker Dal-
tonics). Spectra were acquired in a linear positive ion mode 
with the mass window set to acquire from 2–20 kDa. Mass 
calibration was accomplished externally by use of a mixture 
of standards consisting of insulin, cytochrome c, myoglobin, 
and ubiquitin (Bruker Daltonics, Bremen, Germany).
Data obtained from the mass spectrometry analysis of the 
serum samples were exported as text files for preprocessing 
and further analysis. In-house spectra analysis tools built with 
MATLAB were used to pre-process the mass spectrometry 
data. The spectral preprocessing carried out included baseline 
and noise estimation followed by subtraction of background 
noise using a local (in m/z) noise estimator, normalization 
using total ion current, peak detection with a signal-to-noise 
ratio (S/N) cutoff of 4, and finally peak alignment based on a 
common set of peaks that appear in at least two-thirds of all 
spectra. The preprocessing step resulted in 95 peaks in the 
mass-to-charge (m/z) range of 2–20 kDa on which statistical 
analysis as described below was carried out.
statistical methods
Two sets of analyses were conducted in this study. In the 
first set of analyses, the 95 peaks were tested for association 
with case status. The case group included the 48 women 
with CIN 2 or CIN 3 and the non-case group included the 
79 women with diagnosis #CIN 1. In the second set of analy-
ses, the 95 peaks were tested for association with extreme 
diagnoses of cervical lesions, ie, cases diagnosed with CIN 3 
(n = 23) vs non-cases with diagnosis ,CIN 1 (n = 24).
Within each set of analyses, logistic regression models 
were used to test the association of peak intensities and 
participant characteristics with case status. Using each indi-
vidual peak, 5 initial models were fitted: a bivariate model 
with peak intensity as a predictor of case status, and 4 models 
for interactions between peak intensity and 4 participant 
characteristics (age, BMI, race, and infection with mul-
tiple HR-HPV types), respectively. Each interaction model 
included the main effects for peak intensity and participant 
characteristic, and an interaction term. A model with only the 
peak intensity as predictor assumed that the effects of inten-
sity on case status are similar for all participants. A model 
with a peak-by-characteristic interaction allowed separating 
effects of intensity on case status, according to the levels or 
categories of the characteristic. The statistical significance 
was held at the traditional 0.05 level.
The peaks, characteristics, and peak-by-characteristic 
interactions that individually showed significant association 
with case status were then used to construct a multivariable 
logistic model that predicted the case status. The redundant 
predictors were dropped from the multivariable model using 
a backward-selection algorithm.
Alternative peak selection procedures used to construct 
the multivariable models included least absolute shrinkage 
and selection (LASSO) regression, and least angle regres-
sion (LAR).9 In these procedures, the initial set of predictors 
included all 95 peaks, the 4 participant characteristics, and 
the 380 peak by characteristic interactions.
Measures of sensitivity and specificity were calculated for 
the final multivariable models, as well as for the individual 
predictors used in them. Each logistic regression model 
estimated the probabilities of case status for the range of 
values of the predictors. In order to use the model-predicted 
probabilities to classify individuals into cases or non-cases, 
a cutoff probability value was required. A natural cutoff 
point is 0.5, however, this value might not be optimal. For 
each logistic model, the optimal cutoff probability value was 
determined using a receiver operating characteristic (ROC) 
curve. For each predicted probability taken as cutoff value, 
a ROC curve plots the resulting sensitivity (on the vertical 
axis) vs 1 – specificity (on the horizontal axis). The optimal 
cutoff value is that for which sensitivity and 1 – specificity are 
closest to the ideal values of 1 and 0, respectively. In addition, 
the area under the ROC curve is a measure of the predictive 
ability of the model.10 Areas from 0.7 to 0.8 indicate fair 
predictive ability; areas from 0.8 to 0.9 indicate acceptable 
predictive ability; and areas greater than 0.9 indicate excel-
lent predictive ability.
Leave-one-out cross-validation was conducted for the final 
multivariable logistic models (values for each individual were 
removed from the dataset; then a logistic model was calculated 
with the remaining individuals and used to predict the status 
of the removed individual). For the two peaks that showed the 
strongest association with case status, cross-  validated mea-
sures of sensitivity and specificity were computed separately 
by race. All statistical analyses were conducted using SAS v. 
9.2 software (SAS Institute, Cary, NC; 2008).
Results
sample characteristics
Average ages in years for cases and non-cases were 23.6 
(SD = 3.7) and 23.4 (SD = 4.8), respectively (difference 
in mean age P = 0.85). Average BMI measures in kg/m2 
for cases and non-cases were 25.9 (SD = 6.8) and 26.9 International Journal of Women’s Health 2011:3 submit your manuscript | www.dovepress.com
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(SD = 9.2), respectively (difference in mean BMI P = 0.47). 
The proportions of AAs for cases and non-cases were 39.6% 
(n = 19) and 49.4% (n = 39), respectively (difference in 
proportions, P = 0.28). Among cases, the proportion of 
participants with infections with multiple HPV types was 
47.9% (n = 23); among non-cases, this proportion was 44.3% 
(n = 35, difference in proportions, P = 0.69).
Association of peaks with case status
In the initial set of analyses, which compared 48 cases (CIN 2+) 
with 79 non-cases (#CIN 1), significant bivariate associations 
were detected between case status and the following: 8 peaks, 
1 peak by race interaction, and 1 peak by age interaction. Thus, 
the initial multivariable model included the main effects for 
10 peaks, 2 interaction terms, and main effects for age and 
race. The final multivariable model, however, included only 2 
components: (1) a main effect for peak [m/z = 4459], and (2) a 
race by [m/z = 4154] interaction, which required the inclusion 
of main effects for race and peak [m/z = 4154].
The alternative LASSO and LAR regression procedures 
for peak selection retained only [m/z = 4459] as a predictor. 
Because in the final multivariable logistic model the rela-
tionship between case status and the race by [m/z = 4154] 
interaction was statistically significant in the presence of 
[m/z = 4459], the larger model with both peaks and interac-
tion was preferred and remained as the final model.
At the observed median [m/z = 4459] intensity, the 
model-predicted odds of being CIN 2+ was estimated at 0.58 
(probability of being a case = 0.37). Using the odds of being 
a case at the median intensity as reference, Figure 1 shows 
the model-predicted odds ratios for the observed range of 
intensity values. According to the model, increasing intensity 
of [m/z = 4459] was associated with a higher risk of being 
CIN 2+, regardless of race.
At the observed median [m/z = 4154] intensity, the model-
predicted odds of being CIN 2+ among CAs was estimated 
at 0.75 (probability of being a case = 0.43); among AAs, the 
model predicted odds of being a case was estimated at 0.56 
(probability of being a case = 0.36). Using the odds of being 
CIN 2+ at the median intensity as reference,   Figure 2 shows that 
the model-predicted odds ratios for the observed [m/z = 4154] 
range of intensity values differed by race. According to the 
model, an increasing intensity of [m/z = 4154] was associated 
with a higher risk of being CIN 2+ only among CAs, but had 
an opposite effect among AAs. The interaction term was used 
to model this differential effect by race.
After determining the optimal model-predicted cut-
off probability using a ROC curve (Figure 3), the final 
  multivariate logistic model accurately classified 35 cases 
and 52 non-cases. However, 13 cases were misclassified as 
non-cases, and 27 non-cases were misclassified as cases. 
  Concordance with case status was 68.5%; concordance 
beyond chance, as measured by the Kappa statistic, was 
estimated at 0.37 (95% CI = 0.21, 0.53). The area under the 
ROC curve of 0.72 indicated that the final multivariate model 
had fair predictive ability.
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Figure 1 Association between the intensity of peak m/z = 4459 and odds ratio for 
cIn 2+a.
Note: areference value for odds ratio shown is 0.58 (logistic model predicted odds 
for cIn 2+ at median intensity of the peak).
Abbreviation: cIn, cervical intraepithelial neoplasia.
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Figure 2 Association between the intensity of peak m/z = 4154 and odds ratio for 
cIn 2+ for caucasian Americansa and African Americans.b
Notes:  areference value for odds ratio shown is 0.75 for caucasian Americans 
(logistic model predicted odds for cIn 2+ among caucasian Americans at median 
intensity of the peak);  breference value for odds ratio shown is 0.56 for African 
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median intensity of the peak).
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There was a small expected decrease in the precision 
of the prediction after applying the leave-one-out cross-
validation algorithm. For the final multivariate model, the 
cross-validation algorithm resulted in accurate classification 
of 38 cases and 41 non-cases. Ten cases were misclassified 
as non-cases, and 38 non-cases were misclassified as cases. 
  Concordance with case status was 62.2%; concordance 
beyond chance, as measured by the Kappa statistic, was 
estimated at 0.28 (95% CI = 0.13, 0.43). Cross-validated 
sensitivity and specificity for the final multivariate model as 
well as for each of its two components are shown in Table 1. 
As can be seen in this table, the final model resulted in better 
sensitivity compared with each of its individual components 
alone; however, the models with individual components 
resulted in better specificity compared to the final model. 
This observed variability in the sensitivity and specificity 
measures, when comparing the final model vs the component-
only models, suggests some instability in the prediction, 
caused by variability in the probability of being CIN 2+ that 
remained unexplained by the logistic regression models.
In the subsample of 24 non-cases with diagnosis ,CIN 1 
and 23 cases with CIN 3, the average ages in years for cases 
and non-cases were 23.2 (SD = 3.6) and 22.8 (SD = 3.9), 
respectively (difference in mean age P = 0.73). Average 
BMI measures in kg/m2 for cases and non-cases were 25.0 
(SD = 5.8) and 29.4 (SD = 9.2), respectively (difference in 
mean BMI P = 0.06). The proportions of AAs for cases and 
non-cases were 26% (n = 6) and 70% (n = 17), respectively 
(difference in proportions, P = 0.0034). Among the cases, 
the proportion of participants with infections with multiple 
HR-HPV types was 47.8% (n = 11); among the non-cases, 
this proportion was 45.8% (n = 11, difference in proportions 
P = 0.89).
In the second set of analyses, which utilized the sub-
sample of 24 non-cases with diagnosis ,CIN one and 
23 cases diagnosed with CIN 3, significant univariate 
associations were detected between case status and the 
following: race, 9 peaks, and 2 peak by BMI interactions. 
Thus, the initial multivariable model included 11 peaks, 
2 interactions, and main effects for BMI and race. The final 
multivariable model, however, included only 2 components: 
(1) a main effect for peak [m/z = 4459], and (2) a main effect 
for race. After determining the optimal cutoff point with a 
ROC curve (Figure 4), the final multivariate logistic model 
accurately classified 21 non-cases and 16 cases. However, 
7 cases were misclassified as non-cases, and 3 non-cases 
were misclassified as cases. Concordance with case status 
was 78.7%; concordance beyond chance, as measured by the 
Kappa statistic, was estimated at 0.57 (95% CI = 0.34, 0.80). 
The area under the ROC curve of 0.8152 indicated that the 
model had acceptable predictive ability.
The leave-one-out cross-validation algorithm produced 
similar prediction results compared to those from the original 
model. Measures of cross-validated sensitivity and specific-
ity for the final multivariate model as well as for each of its 
two components are shown in Table 2. As can be seen in 
this table, the final model provided more accurate specific-
ity compared with each of its individual components alone, 
but the sensitivity decreased compared to the race-only 
model. Again, this observed variability in the sensitivity 
and specificity measures, when comparing the final model 
vs the component-only models, suggests some instability 
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Table 1 Cross-validated screening test measures for the final multivariate model and individual models with the two components of 
the final model predicting cervical intraepithelial neoplasia (CIN) 2+ vs #cIn 1 (n = 127)
Model: Predictor(s) Sensitivity Specificity Cutoff prob.a
Final model: [m/z = 4459], race*[m/z = 4154], race, [m/z 4154] 79% 52% 0.32
Model with component 1 only: [m/z = 4459] 69% 58% 0.34
Model with component 2 only: race*[m/z = 4154], race, [m/z = 4154] 58% 58% 0.38
Note: aOptimal cutoff probabilities were determined by receiver operating characteristic curves.International Journal of Women’s Health 2011:3 submit your manuscript | www.dovepress.com
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in the prediction, caused by variability in the probability 
of being a case that remained unexplained by the logistic 
regression models.
Prediction results by race
After determining that peaks [m/z = 4459] and [m/z = 4154] 
showed the strongest association with case status, the predic-
tion results using these two peaks were compared by race. 
Table 3 shows cross-validated sensitivity and specificity 
measures tabulated by race, for a model predicting CIN 2+ 
using peak [m/z = 4459] as the only predictor. Because the 
effect of increasing [m/z = 4154] intensity on CIN 2+ was 
opposite by race (Figure 2), two models predicting CIN 2+, 
using [m/z = 4154] intensity as the only predictor, were 
fitted for each race, respectively. Cross-validated sensitiv-
ity and specificity for these models are shown in Table 4. 
Table 5 shows cross-validated sensitivity and specificity 
measures tabulated by race, for a model predicting CIN 3 
using peak [m/z = 4459] as the only predictor, among the 
subsample of 24 non-cases with diagnosis ,CIN 1 and 
23 cases diagnosed with CIN 3. As can be seen in this table, 
sensitivity was higher for CAs, but specificity was higher 
for AAs, suggesting again that the predictive ability of the 
[m/z = 4459] intensities on extreme diagnoses might vary 
by race.
Discussion
An important application of MALDI-TOF MS is the simulta-
neous analysis of multiple proteins to establish “fingerprint” 
profiles that discriminate disease from non-disease. This is 
an important approach, since no single biomarker or protein 
alone will improve the early detection/diagnosis of diseases, 
including cancer or pre-cancers. Body fluids, such as serum, 
are a source of putative protein biomarkers with the potential 
to elucidate organ-specific carcinogenic events. Because of 
its high sensitivity for proteins in the low molecular weight 
range and because of its capability of high throughput screen-
ing, MALDI-TOF MS has been used to distinguish healthy 
controls from patients diagnosed with several cancers includ-
ing the colon, lung, ovary, breast and esophagus.11–15 Previous 
studies have also documented differences in serum protein 
profiles between cervical cancer and healthy   controls.16 
Three differentially expressed potential biomarkers with 
relative molecular weights of 3974 Da, 4175 Da and 5906 Da 
identified in this study demonstrated ∼90% sensitivity and 
specificity in disguising cervical cancer from controls. To 
our knowledge, the current study is the first to document 
the usage of MALDI-TOF-MS technology in the analysis 
of serum protein profiles of patients diagnosed with cervi-
cal pre-cancer and evaluated differences in sensitivity and 
specificity of protein peaks by race.
We focused on women infected with HPV 16 as this virus 
is the most frequent causative agent for developing cervical 
cancer world-wide.17 Even though only a fraction of women 
infected with HPV 16 develops CIN 2+, these lesions have 
the highest rate of progression to CC.18 Further, the recur-
rence rate of CIN 2+ after a loop electrosurgical excision 
procedure was shown to be significantly higher among 
those who were tested positive for HPV 16 before and after 
the procedure.19 Therefore, identification of this fraction of 
women and treatment of their lesions and closer follow-up 
after treatment are important unmet medical needs in the 
current management protocols. Currently available tests do 
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Table 2 Cross-validated screening test measures for the final multivariate model and individual models with the two components of 
the final model predicting cervical intraepithelial neoplasia (CIN) 3 vs ,cIn 1 (n = 47)
Model: Predictor(s) Sensitivity Specificity Cutoff prob.a
Final model: [m/z 4459], race 70% 87% 0.60
Model with component 1 only: [m/z 4459] 61% 75% 0.50
Model with component 2 only: race 74% 71% 0.72
Note: aOptimal cutoff probabilities were determined by receiver operating characteristic curves.International Journal of Women’s Health 2011:3 submit your manuscript | www.dovepress.com
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not have adequate specificity for identifying women with 
HPV 16-associated CIN 2+.
In our population, 40% of women infected with HPV 16 
were diagnosed with CIN grades higher than 2 (CIN 2+). 
Identification, treatment, and closer follow-up of these women 
would offer a cost-effective strategy to reduce the cervical 
cancer burden. A meta-analysis showed that detecting any 
HR-HPV by the Hybrid Capture 2 test among women with 
abnormal pap demonstrated 97.2% sensitivity for detecting 
CIN 2+ and 97.1% sensitivity for detecting CIN 3+. This 
analysis also demonstrated a pooled specificity of 30.6% and 
26.1% when the outcome was CIN 2+ and CIN 3+ respec-
tively.20 A recent study demonstrated that the sensitivity 
of the HPV 16/18 genotyping test for detection of CIN 2+ 
was .93% while the specificity of the test for detection of 
CIN 2+ and CIN 3+ was 44.2% and 43%, respectively.21
Two protein peaks identified by our study demonstrated 
higher specificity for identifying CIN 2+ than these pub-
lished studies. An increasing intensity of [m/z = 4459] was 
  associated with a higher risk of being a case, regardless of race 
with a specificity of 58% for CIN 2 and a specificity of 75% 
for CIN 3. Further, to our knowledge for the first time, we 
also document interesting racial differences in the associations 
between peak intensities and higher risk of being diagnosed 
with CIN 2+. An increasing intensity of [m/z = 4154] was not 
only associated with a higher risk of being a case only among 
CAs, but also had an opposite effect among African AAs. With 
[m/z = 4459], the specificity was higher for AAs, but the sensitiv-
ity was higher for CAs suggesting that the predictive ability of the 
[m/z = 4459] peak intensities varies by race. With [m/z = 4154], 
on the other hand, the sensitivity was similar for the two races, 
but the specificity was higher for AAs,   indicating that the peak 
had slightly better predictive ability among AA women.
This report suggests a capacity of serum protein profiles 
to differentiate between HPV 16 positive women free of true 
pre-neoplastic lesions (#CIN 1) and women diagnosed with 
higher grades of CIN, especially CIN 3, in our population 
of women infected with HPV 16. In the statistical analyses, 
infection with other types of HR-HPVs was used as a predic-
tor of case status, by itself and as an interaction with the m/z 
peaks, but no significant association was found. Therefore, 
these results suggest that it is unlikely that co-infections with 
other HPVs interfere with identifying CIN lesions in women 
infected with HPV 16. Further, the results also suggested that 
specific serum profiles might be useful for differentiating 
CIN cases from non-cases in AAs and CAs.
Identification of specific proteins associated with peaks 
that are significantly different between #CIN 1 and CIN 2+ 
by race may potentially lead to the development of new 
screening tests which are suitable in different racial groups. 
Identification of these serum proteins and development 
of antibody-based tests, such as ELISA, may lead to the 
development of cost-effective, non-invasive, sensitive, and 
simple to use tests. Further, serum based screening tests are 
likely to be more acceptable than cervical cell based tests in 
populations where the prevalence of obesity is high, as studies 
indicate lower rates of cervical cancer screening among obese 
compared with non-obese women due to embarrassment and 
perceived weight stigma.22 Also, lack of appropriately sized 
equipment for examination of obese women in some clinical 
settings may lead to poor quality cervical cell samples that 
result in unreliable or invalid test results. Therefore, serum 
based screening biomarkers are likely to be extremely useful 
in this group of women. Collectively, these results suggest the 
need for developing race-specific markers to maximize the 
usefulness of serum protein based tests as effective screening 
tools. Despite intense screening in the past decades, higher 
rates of cervical cancer still persist among some sub-groups 
of women, including AA women.23 Race-specific screening 
tests are likely to reduce these disparities.
Although these prediction results using serum biomark-
ers are promising, there was still a considerable amount of 
variability in the probabilities of case status that remained 
Table  3  cross-validated  screening  test  measures  by  race  for 
a  model  predicting  cervical  intraepithelial  neoplasia  (cIn)  2+ 
vs #cIn 1, using peak [m/z = 4459] as the only predictora
Race n Sensitivity Specificity
African American 58 58% 64%
caucasian 69 76% 53%
combined 127 69% 58%
Note: acutoff probability was 0.34.
Table 4 cross-validated screening test measures by race for 
a  model  predicting  cervical  intraepithelial  neoplasia  (cIn)  2+ 
vs #cIn1, using peak [m/z = 4154] as the only predictor
Race n Sensitivity Specificity Cutoff prob.
African American 58 63% 64% 0.32
caucasian 69 62% 53% 0.40
Table 5 cross-validated screening test measures by race for a 
model predicting cervical intraepithelial neoplasia (cIn) 3 vs ,cIn 1, 
using peak [m/z = 4459] as the only predictor (n = 47)a
Race n Sensitivity Specificity
African American 23 50% 76%
caucasian 24 65% 71%
combined 47 61% 75%
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unexplained by the statistical models used in this study. 
A classical screening approach used in this study permitted 
the detection of the two individual peaks associated with 
case status. Only interactions between individual peaks and 
4 participant characteristics (age, BMI, race, and infection 
with multiple HR-HPV types) were considered. However, 
peak by peak interactions (or peak by peak profiles) were not 
considered in either the classical screening approach or in the 
alternative LASSO and LAR peak selection procedures, due 
to the overwhelming number of possibilities. With 95 peaks, 
restricting the interactions or profiles to only a maximum of 
four peaks at a time, there are 4465 possible 2-way interac-
tions, 138,415 possible 3-way interactions, and 3,183,545 
possible 4-way interactions. Because interactions (or peak 
by peak profiles) cannot be ruled out from being associated 
with case status, further examination of these peak by peak 
profiles using larger sample sizes and data mining techniques 
is warranted in future studies.
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